Should Ivabradine be First‐Line Therapy for Inappropriate Sinus Tachycardia?

current at low concentration with a use-dependent way, which manifests as a slowly progressing accumulation of the drug during repetitive channel activation/deactivation cycles. Thus, unlike beta-blockers, Ivabradine, in smaller doses, results in a more substantial blocking effect at higher tachycardic rates and, therefore, more successful in the treatment of IST. The current literature review, which includes a small number of patients, has shown that Ivabradine lowered basal, mean, and maximal HR and was associated with symptomatic improvement. We have described the unique and specific mechanism of action, along with its safety profile, which supports Ivabradine's role as the first-line therapy for the resolution of IST.